Rodda et al. (2020) performed a longitudinal assessment of individuals recovered from mild COVID-19 to determine whether they develop and sustain multifaceted SARS-CoV-2-speciﬁc immunological memory.
They determined that recovered individuals developed SARS-CoV-2-speciﬁc immunoglobulin (IgG) antibodies, neutralizing plasma, and memory B and memory T cells that persisted for at least 3 months.
Their data further reveals that SARS-CoV-2-speciﬁc IgG memory B cells increased over time.
Additionally, SARS-CoV-2-speciﬁc memory lymphocytes exhibited characteristics associated with potent antiviral function: memory T cells secreted cytokines and expanded upon antigen re-encounter, whereas memory B cells expressed receptors capable of neutralizing virus when expressed as monoclonal antibodies.
Therefore, mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks of antiviral immunity.
Lauren B. Rodda, Jason Netland, Laila Shehata, Kurt B. Pruner, Peter A. Morawski, Christopher D. Thouvenel, Kennidy K. Takehara, Julie Eggenberger, Emily A. Hemann, Hayley R. Waterman, Mitchell L. Fahning, Yu Chen, Malika Hale, Jennifer Rathe, Caleb Stokes, Samuel Wrenn, Brooke Fiala, Lauren Carter, Jessica A. Hamerman, Neil P. King, Michael Gale, Daniel J. Campbell, David J. Rawlings, Marion Pepper,
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19,
Cell, 2020, ISSN 0092-8674, https://doi.org/10.1016/j.cell.2020.11.029.